Previous 10 | Next 10 |
EDINBURGH, United Kingdom, Nov. 14, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies 2019 London Healthcare Conference in London, UK...
NuCana (NASDAQ: NCNA ): Q3 GAAP EPS of -£0.12 beats by £0.09. More news on: NuCana plc, Earnings news and commentary, Healthcare stocks news, , Read more ...
Opens Phase III Global Biliary Tract Cancer Study (NuTide:121) with Potential for Accelerated Approval Filing Focusing Resources on Key Value-Driving Programs of Biliary Tract Cancer and Colorectal Cancer Cash and Cash Equivalents to Fund Operations into the Second Half of 20...
NUC-3373: Favorable Pharmacokinetic Profile Demonstrated NUC-7738: Multiple Anti-Cancer Mechanisms of Action Identified, including Inhibition of the mTOR Pathway BOSTON, Oct. 29, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced results from two of its clinical stage...
The FDA has cleared NuCana's (NASDAQ: NCNA ) IND for its Phase III study (NuTide:121) of Acelarin (NUC-1031) in combination with cisplatin for patients with previously untreated locally advanced or metastatic biliary tract cancer. More news on: NuCana plc, Healthcare stocks news, Rea...
Global NuTide:121 Study will Enroll up to 828 Patients and Compare Acelarin plus Cisplatin to Gemcitabine plus Cisplatin Primary Endpoints of Overall Survival and Objective Response Rate Three Interim Analyses, Including Two Designed to Support Accelerated Approval EDINBU...
EDINBURGH, United Kingdom, Aug. 29, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Morgan Stanley 17th Annual Global Healthcare Conference i...
EDINBURGH, United Kingdom, Aug. 27, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host one-on-one meetings at Citi’s 14th Annual Biotech Conference in Boston on September 5 th ...
Investors appear to be on board with sell-side shops as they shrug off the implications of the failed investigator-sponsored late-stage study evaluating NuCana's ( NCNA -0.5% ) lead candidate Acelarin compared to gemcitabine in metastatic pancreatic cancer. Earlier this week, the company ...
NuCana (NASDAQ: NCNA ): Q2 GAAP EPS of - £ 0.14 beats by £ 0.05. More news on: NuCana plc, Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Jaguar Health Inc. (JAGX) rose 50.1% to $0.1783 on volume of 599,794,977 shares WiSA Technologies Inc. (WISA) rose 248.6% to $6.1 on volume of 197,912,579 shares PROSHARES TRUST (SQQQ) rose 0.0% to $11.44 on volume of 182,001,060 shar...
A look at the top 10 most actives in the United States Jaguar Health Inc. (JAGX) rose 37.1% to $0.1629 on volume of 102,747,129 shares WiSA Technologies Inc. (WISA) rose 69.1% to $2.96 on volume of 24,734,833 shares Peraso Inc. (PRSO) rose 37.0% to $1.7393 on volume of 23,546,162 shares ...
EDINBURGH, United Kingdom, April 16, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that the Company’s previously disclosed plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares from one (1) ADS, representing one (1) ordinar...